Singaporean startup FathomX scores virtually $2M to hasten breast most cancers AI improvement

Date:

Share post:



AI startup FathomX from Singapore has raised SG$2.24 million ($1.6 million) from an undisclosed investor within the lead-up to its Sequence A funding spherical. 

This follows its seed funding spherical in April final 12 months the place it raised SG$500,000 (over $350,000). 

WHAT IT DOES

A spin-off from the Nationwide College of Singapore and the Nationwide College Well being System, FathomX provides an AI-powered mammography assist software known as FxMammo. 

The screening answer has been discovered to be extremely correct in detecting most cancers in dense breasts amongst Asian ladies. It is usually in a position to scale back false positives for interval cancers, or cancers which might be recognized in between routine screening episodes. Moreover, it enhances scientific workflow by decreasing screening time and workforce. 

The startup is carefully working with the Diagnostics Growth Hub of Singapore’s Company for Science, Know-how and Analysis and Hewlett Packard Enterprise to develop FxMammo into software program as a medical gadget.

WHAT IT’S FOR

Its contemporary funding will assist speed up the tempo of its product improvement and its acquisition of regulatory approvals. Furthermore, the funding will assist its ongoing multi-site validation examine for FxMammo throughout eight markets in Asia-Pacific, in addition to facilitate extra analysis and industrial collaborations.

MARKET SNAPSHOT

South Korean startup Lunit is presently main the AI diagnostic area in APAC. It additionally provides an AI mammography assist software, Lunit INSIGHT MMG, which analyses mammograms with 96% accuracy. It just lately unveiled a brand new digital breast tomosynthesis software which accelerates the studying course of by selecting a 3D slice picture with suspicious lesions amongst a number of photos.

One other startup, Whiterabbit, has additionally just lately launched its personal AI breast most cancers screening answer known as WRDensity, which was given an FDA 510(okay) clearance in 2020. It makes use of AI to ship knowledge on breast density, which is a threat issue for breast most cancers. New Zealand-based Volpara Well being is one other firm that has acquired the identical US FDA approval for its breast most cancers detecting platform, Volpara Imaging Software program.



Supply hyperlink

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Related articles